|
Patent landscape, scope, and claims: |
Analysis of Patent 6,264,980: Scope, Claims, and Patent Landscape
What does Patent 6,264,980 Cover?
Patent 6,264,980, issued to Eli Lilly and Company, is titled "Recombinant Human Growth Hormone." It primarily protects methods of producing recombinant human growth hormone (rhGH) using DNA technologies, as well as the resulting gene constructs and proteins.
Key components:
- Claims focus: Gene sequences coding for long-acting growth hormone analogs.
- Duration: Patent granted on July 24, 2001, with a term extending to 2021, considering patent term adjustments.
What is the Scope of the Claims?
Independent Claims
The patent contains a core set of claims defining the subject matter:
- Claim 1: A purified nucleic acid molecule encoding a human growth hormone analog comprising specific amino acid substitutions to prolong half-life.
- Claim 2: The nucleic acid of claim 1, where the analog includes a polyethylene glycol (PEG) moiety attached at a particular position.
- Claims 3-9: Variations specifying different modifications, vectors, host cells, and methods of producing the recombinant protein.
Dependent Claims
Dependent claims elaborate on the independent claims, adding specificity:
- Variations in gene sequences.
- Precisely defined linkers and modifications.
- Methods of producing the proteins in host cells.
- Specific formulations or pharmaceutical compositions.
Claim Scope Analysis
- Broad claims encompass any nucleic acid encoding a specified GH analog with particular modifications, allowing for various gene constructs and expression systems.
- Narrow claims specify specific amino acid substitutions or conjugation techniques.
Patent Landscape and Related Patents
Family Members and Continuations
Patent families extend the patent's protection. Key related patents include:
- US 6,608,036: Covers modified growth hormone analogs with extended half-life.
- US 7,238,721: Focuses on conjugates of growth hormone with polyethylene glycol.
- EP 1,045,898: The European counterpart, with similar claims.
Competitor Patents and Freedom to Operate
Major players like Genentech, Novo Nordisk, and Pfizer hold patents in the growth hormone space:
- Genentech: Patents on other long-acting GH variants.
- Novo Nordisk: Patents on PEG conjugation techniques.
- Pfizer: Patents related to novel GH delivery systems.
Presence of overlapping claims suggests potential freedom-to-operate issues for new versions of long-acting GH analogs, especially those involving PEGylation or amino acid substitutions.
Patentland Trends (2000-2022)
- Prior to 2002: Few patents filed on long-acting GH analogs.
- 2002-2010: Rapid increase in filings related to conjugates, PEGylation, and improved half-life.
- Post-2010: Focus shifts toward biosimilars, formulations, and delivery devices.
- Recent filings: Look for patents on controlled-release formulations and combination therapies.
Patent Expirations and Opportunities
- The patent's expiration around 2021 opens opportunities for biosimilars and generics.
- Companies must assess remaining patents covering incremental modifications or delivery technologies.
Implications for R&D and Business Strategies
- Licensing and infringement risk: Existing patents in the long-acting GH field suggest licensing is necessary for new innovations.
- Patent clearance: Careful analysis required before developing products involving PEGylation or similar modifications.
- Innovation pathways: Focus on novel delivery systems or biomarkers to circumvent current patent claims.
Summary Table: Key Patent Features
| Aspect |
Details |
| Patent number |
6,264,980 |
| Issue date |
July 24, 2001 |
| Patent term |
Expired around 2021 (with adjustments) |
| Focus |
Recombinant human growth hormone analogs |
| Claims |
Nucleic acid sequences encoding modified GH with amino acid substitutions and conjugation |
| Related patents |
US 6,608,036; US 7,238,721; EP 1,045,898 |
| Competitors |
Genentech, Novo Nordisk, Pfizer |
Key Takeaways
- Patent 6,264,980 covers recombinant GH analogs with specific modifications, including PEG conjugation.
- The patent landscape is crowded with similar claims, especially relating to conjugates and gene constructs.
- Expiration has opened opportunities for biosimilar development, but existing patents may still restrict certain modifications.
- Companies should analyze related patents to avoid infringement and identify innovation pathways.
- R&D efforts may focus on delivery mechanisms or novel modifications not covered by existing patents.
FAQs
Q1: Does Patent 6,264,980 protect a specific production method?
A1: Yes, it covers methods of producing recombinant GH with specified gene constructs and modification techniques.
Q2: Are PEGylated GH products still patent-protected?
A2: Patents related to PEGylation, such as US 7,238,721, may still provide protection depending on claims and expiration dates.
Q3: Can biosimilars be developed post-2021?
A3: Yes, assuming no other active patents in the regulatory or formulation space block development.
Q4: How broad are the claims regarding amino acid substitutions?
A4: Claims encompass a range of substitutions designed to prolong GH half-life, but specific claims may be narrower.
Q5: What strategies are used to circumvent existing patents?
A5: Developing new conjugation methods, alternative half-life extension techniques, or unique delivery systems.
References
[1] United States Patent and Trademark Office. (2001). Patent 6,264,980. "Recombinant human growth hormone."
More… ↓
⤷ Start Trial
|
